Improved β-cell Function and Prolonged Remission of Diabetes Type 1 by GLP-1 Agonist Treatment in Newly Diagnosed Adolescences

Authors: Spyridon Zarogiannis

Affiliations: University of Glasgow, College of Medical, Veterinary & AMP; Life Sciences, Institute of Cardiovascular & AMP; Medical Sciences, Glasgow, Greece

Aims: To investigate the effect of GLP-1 agonists on the β-cell function and on the remission phase of the diabetes type 1. Background: GLP-1 agents are known to have positive effects in patients with diabetes type 2, but their benefits in diabetes type 1 have only been investigated the last few years. In the current research proposal, it is suggested that GLP-1 in addition to insulin therapy, can preserve β-cell function and remission phase. Methods: Fifty-eight newly diagnosed adolescences (10-17 years old) are enrolled in this randomized, open label, controlled trial for two years duration. Subjects are randomly assigned to receive either exenatide twice daily or no exenatide in addition to intensified insulin therapy. Outcomes: The primary outcome is change in stimulates C-peptide levels and the secondary outcome is preservation of remission phase. Expected Impact: Reduced stimulated C-peptide levels, insulin requirements, improved glycemic control and longer remission phase in exenatide group.

• Fulltext Article